Caribou Biosciences (CRBU) stock is set to take center stage as the company refocuses on key oncology programs amid layoffs to extend cash runway. Read more here.

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates ...

In honor of the 20th anniversary of ’The Milk Of Human Kindness,’ we’re looking back at Caribou’s albums and ranking them all.

Caribou migration patterns are shrinking Habitat loss and declining population affecting caribou travel between locations Date: March 5, 2025 Source: University of British Columbia Okanagan campus ...

John Butcher has been at the helm of Caribou Coffee over an eventful seven years. Under his tenure, the Brooklyn Center-based coffee chain launched a new domestic franchising program and underwent ...

The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, T1D, and HIV.

Our Caribou auto loan review covers what you need to know to decide whether it’s the right choice for you.

Is Caribou Biosciences a buy on the pullback? Today's sell-off presents a good buying opportunity, in my view, for aggressive investors who are willing to bet on Caribou's success over the long term.

Cell-type-specific in vivo delivery of genome editing molecules is the next breakthrough that will drive biological discovery and transform the field of cell and gene therapy. Here, we discuss recent ...

Caribou Coffee hands over roasting operations in $260M deal, focuses on coffeehouses The company said the Brooklyn Center roastery will still roast all of its coffee.

Caribou Coffee is offloading its roasting operations onto a sister company to focus exclusively on its retail business. On Thursday, the Minnesota-based coffee company announced that JDE Peet’s ...